Search our Database of Scientific Publications and Authors

I’m looking for a

    1084 results match your criteria Clinical Genitourinary Cancer [Journal]

    1 OF 22

    Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.
    Clin Genitourin Cancer 2017 Aug 24. Epub 2017 Aug 24.
    University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address:
    Background: Venous thromboembolism (VTE) is common in cancer patients, but there is limited data on patients with urothelial tract tumors (UTT). We previously identified several associative factors for increased VTE rates in patients with metastatic UTT. In this study, we assessed the frequency, associative factors, and impact on survival of VTE in patients with locoregional UTT. Read More

    Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database.
    Clin Genitourin Cancer 2017 Aug 12. Epub 2017 Aug 12.
    Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:
    Background: Poor-risk patients with metastatic renal-cell carcinoma remain poorly characterized in prospective clinical trials. Therefore, we sought to provide a comprehensive analysis of this patient population, defined by 3 widely used prognostic models, treated with targeted therapy.

    Patients And Methods: We conducted a pooled retrospective analysis of 4736 metastatic renal-cell carcinoma patients treated on phase 2 and 3 clinical trials. Read More

    External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Population-based Study.
    Clin Genitourin Cancer 2017 Aug 24. Epub 2017 Aug 24.
    Department for Gynaecology and Gynaecologic Oncology, Medical University of Vienna, Vienna, Austria.
    Background: We sought to externally validate our pathologic nodal staging score (pNSS) model, which allows for quantification of the likelihood that a pathologically node-negative patient will not have lymph node (LN) metastasis after radical prostatectomy for prostate cancer (PCa) in a population-based cohort.

    Patients And Methods: We analyzed data from 50,598 patients treated with radical prostatectomy and pelvic LN dissection using the Surveillance, Epidemiology, and End Results database. We estimated the sensitivity of pathologic nodal staging using a β-binomial model and developed a novel pNSS model, which represents the probability that a patient's PCa has been correctly staged as node negative as a function of the number of examined LNs. Read More

    Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease.
    Clin Genitourin Cancer 2017 Aug 31. Epub 2017 Aug 31.
    GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA. Electronic address:
    Background: Men who present with metastatic disease can have de novo or primary progressive disease. We characterized and compared the outcomes between these 2 groups.

    Patients And Methods: A retrospective cross-sectional analysis from a single institution of de novo versus primary progressive metastatic patients during a 2-year consecutive period was undertaken. Read More

    Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer.
    Clin Genitourin Cancer 2017 Aug 24. Epub 2017 Aug 24.
    Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:
    Introduction: Knowledge of the comparative oncologic outcomes of histologic variants after radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) relies on small case series. We compared the effect of pure squamous cell carcinoma, adenocarcinoma, and neuroendocrine carcinoma compared with pure urothelial carcinoma (PUC) on overall survival (OS) and pathologic tumor, lymph node, and surgical margin status after RC.

    Patients And Methods: Using the National Cancer Database, we retrospectively examined patients undergoing RC for MIBC from 2003 to 2011. Read More

    Oligometastatic Renal Cell Carcinoma With Sarcomatoid Differentiation Demonstrating Variable Imaging Phenotypes on (68)Ga-PSMA and (18)F-FDG PET/CT: A Case Report and Review of the Literature.
    Clin Genitourin Cancer 2017 Aug 23. Epub 2017 Aug 23.
    Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; The Sir Peter MacCallum Department of Oncology, the University of Melbourne, Parkville, Victoria, Australia.

    Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.
    Clin Genitourin Cancer 2017 Aug 12. Epub 2017 Aug 12.
    Department of Medical Oncology, Gustave Roussy, Villejuif, France.
    Background: Everolimus (E) and axitinib (A) have been standard treatments for patients with metastatic renal cell carcinoma after failure of first-line therapy (1L) with vascular endothelial growth factor-targeted therapy. This study aims to compare both drugs in a large comprehensive cancer center.

    Methods: Patient characteristics and outcome data from all patients with metastatic renal cell carcinoma who received E or A as second-line therapy at Gustave Roussy from April 2007 to May 2015 have been recorded. Read More

    Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
    Clin Genitourin Cancer 2017 Aug 3. Epub 2017 Aug 3.
    Department of Urology, Chiba University Hospital, Chiba, Japan.
    Introduction: Reductions in testosterone concentration play a significant role in the treatment of prostate cancer. We studied the role of testosterone as a prognostic marker for advanced prostate cancer (stage C or higher) treated with primary androgen-deprivation therapy (ADT).

    Patients And Methods: A total of 348 patients were treated using ADT as first-line therapy for prostate cancer at Chiba University Hospital between 1999 and 2016. Read More

    Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry.
    Clin Genitourin Cancer 2017 Aug 9. Epub 2017 Aug 9.
    Department of Antitumor Drug Therapy, Rostov Research Institute of Oncology, Rostov-on-Don, Russia.
    Background: The 5-year overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC) has been rarely reported. The aim of the RENSUR5 registry study was to obtain real-world data on the use of therapy for mRCC and assess the 5-year OS in the Russian population.

    Patient And Methods: Patients were retrospectively identified at 11 cancer centers in different regions of Russia (Astrakhan, Barnaul, Ekaterinburg, Kazan, Krasnoyarsk, Obninsk, Omsk, Rostov-on-Don, Samara, St. Read More

    Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma.
    Clin Genitourin Cancer 2017 Aug 10. Epub 2017 Aug 10.
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:
    Background: Patients with sarcomatoid renal-cell carcinomas (sRCC) have poor outcomes and limited treatment options. Preclinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factor-targeted therapies. We designed a phase 2 trial to evaluate the efficacy and safety of capecitabine, gemcitabine, and bevacizumab in sRCC. Read More

    Survival Outcomes of Radical Prostatectomy Versus Radiotherapy in Intermediate-Risk Prostate Cancer: A NCDB Study.
    Clin Genitourin Cancer 2017 Aug 9. Epub 2017 Aug 9.
    Creighton University School of Medicine, Omaha, NE.
    Background: Studies of various prostate cancer patient cohorts found men receiving external-beam radiotherapy (EBRT) had higher mortality than men undergoing radical prostatectomy (RP). Conversely, a recent clinical trial showed no survival differences between treatment groups. We used the National Cancer Data Base (NCDB) to evaluate overall survival in intermediate-risk (T2b-T2c or Gleason 7 [grade group II or III] or prostate-specific antigen 10-20 ng/mL) prostate cancer patients undergoing EBRT with or without androgen deprivation therapy (ADT), RP, or no initial treatment. Read More

    Radiofrequency Ablation for Renal Cancer in Von Hippel-Lindau Syndrome Patients: A Prospective Cohort Analysis.
    Clin Genitourin Cancer 2017 Aug 10. Epub 2017 Aug 10.
    Division of Urology, Department of Surgical Science, A. O. Città della Salute e Della Scienza di Torino-presidio Molinette, University of Turin, Turin, Italy.
    Introduction: Management of renal-cell carcinoma (RCC) in patients with Von Hippel-Lindau syndrome (VHL) represents a clinical dilemma: the oncologic outcomes must be weighed against preservation of renal function. Radiofrequency ablation (RFA) is currently used in selected cases for treatment of small-size RCC. The aim of this study was to evaluate the safety, complications, and functional and oncologic outcomes of RFA in the treatment of RCC in VHL patients. Read More

    Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer 2017 Aug 10. Epub 2017 Aug 10.
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
    Background: We evaluated the incidence and effect of thromboembolic events (TEEs) in patients with muscle-invasive bladder cancer treated with preoperative chemotherapy (POC) and radical cystectomy (RC) with pelvic lymph node dissection (PLND).

    Patients And Methods: We performed a retrospective review of all patients who had undergone POC followed by RC plus PLND for muscle-invasive bladder cancer from June 2000 to January 2013 (n = 357). The chemotherapy type (neoadjuvant vs. Read More

    National Trends and Predictors of Locally Advanced Penile Cancer in the United States (1998-2012).
    Clin Genitourin Cancer 2017 Aug 12. Epub 2017 Aug 12.
    Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL.
    Background: We analyzed the trends in presentation of squamous cell carcinoma (SCC) of the penis and determined the socioeconomic predictors for locally advanced (cT3-cT4) disease in the United States.

    Patient And Methods: The National Cancer Database was queried for patients with clinically nonmetastatic penile SCC and staging available from 1998 to 2012. Temporal trends per tumor stage were evaluated, and a multivariable logistic regression model was used to identify predictors for advanced presentation during the study period. Read More

    Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience.
    Clin Genitourin Cancer 2017 Aug 3. Epub 2017 Aug 3.
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address:
    Background: Salvage radiotherapy (SRT) has been successfully used for recurrent prostate cancer after radical prostatectomy; however, the optimal timing of SRT remains controversial. Our objective was to identify the risk factors for disease progression after SRT, with a focus on the pre-SRT prostate-specific antigen (PSA) levels in the modern era of PSA testing.

    Patients And Methods: We performed a retrospective review of 551 consecutive patients who had undergone postradical prostatectomy SRT for recurrent prostate cancer from 2000 to 2013. Read More

    Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.
    Clin Genitourin Cancer 2017 Aug 2. Epub 2017 Aug 2.
    Dana-Farber Cancer Institute, Boston, MA; Hospital De Mar Research Institute-IMIM, Barcelona, Spain. Electronic address:
    Background: Upper tract urothelial carcinomas (UTUCs) are increasingly recognized as separate malignancies. Additional insight into clinical outcomes and key prognostic factors are needed.

    Objectives: To detail outcomes of patients with UTUCs recurring after radical nephroureterectomy (RNU) and to determine a risk score that predicts outcomes of patients with non-lymph node distant metastasis. Read More

    Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors.
    Clin Genitourin Cancer 2017 Aug 3. Epub 2017 Aug 3.
    Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA. Electronic address:
    Background: To our knowledge, no studies have evaluated the association between smoking and stage at diagnosis or survival among men with germ cell tumors (GCTs). We therefore evaluated the association between smoking and GCT presentation and outcomes.

    Methods: Electronic medical records of 1161 patients with GCT treated at Dana-Farber Cancer Institute between 1997 and 2013 were reviewed. Read More

    Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer.
    Clin Genitourin Cancer 2017 Aug 15. Epub 2017 Aug 15.
    Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY. Electronic address:
    Background: We assessed the role of N-cadherin as a prognostic biomarker in patients with invasive bladder cancer (BCa) who had undergone radical cystectomy (RC).

    Patients And Methods: The present retrospective single-center study included 433 BCa patients who had undergone RC and bilateral lymph node dissection. Formalin-fixed paraffin tissue microarrays were stained with an anti-N-cadherin monoclonal mouse antibody. Read More

    Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients.
    Clin Genitourin Cancer 2017 Aug 1. Epub 2017 Aug 1.
    Department of Urology, Mayo Clinic, Rochester, MN. Electronic address:
    Background: Radical cystectomy (RC) represents a treatment option for patients with high-grade non-muscle-invasive bladder cancer (HG-NMIBC); however, perioperative morbidity is not insignificant, particularly in elderly patients. We sought to evaluate the associations of age with utilization and outcomes of RC for HG-NMIBC.

    Patients And Methods: Patients with HG-NMIBC diagnosed between 2004 and 2013 were identified in the National Cancer Database and stratified by age: ≤ 60, 61-70, 71-80, and > 80 years. Read More

    Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone.
    Clin Genitourin Cancer 2017 Jul 25. Epub 2017 Jul 25.
    BC Cancer Agency, Vancouver, BC, Canada.
    Background: Radiographic progression-free survival (rPFS) is associated with overall survival (OS) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients. Using readily assessable baseline clinical and laboratory parameters, we developed a prognostic index model for rPFS in chemotherapy-naïve mCRPC patients without visceral disease who were treated with abiraterone acetate plus prednisone.

    Methods: Data from the abiraterone acetate plus prednisone arm of COU-AA-302 were used. Read More

    Favorable Gleason 3 + 4 Prostate Cancer Shows Comparable Outcomes With Gleason 3 + 3 Prostate Cancer: Implications for the Expansion of Selection Criteria for Active Surveillance.
    Clin Genitourin Cancer 2017 Aug 3. Epub 2017 Aug 3.
    Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea; Department of Urology, Seoul National University College of Medicine, Seoul, Korea. Electronic address:
    Background: To investigate the feasibility of active surveillance (AS) in biopsy Gleason score (GS) 3 + 4 prostate cancer (PCa), we compared the outcomes of biopsy GS 3 + 3 and 3 + 4 PCa after radical prostatectomy.

    Patients And Methods: We analyzed the data of 1491 patients undergoing radical prostatectomy for biopsy GS 3 + 3 or 3 + 4 PCa who fulfilled the low-risk criteria of the National Comprehensive Cancer Network guidelines regardless of GS. The favorable GS 3 + 4 group was defined as having core involvement ≤ 50%, prostate-specific antigen density ≤ 0. Read More

    Validation of the Eighth AJCC New Substages for Bladder Cancer Among Different Staging Contexts.
    Clin Genitourin Cancer 2017 Aug 3. Epub 2017 Aug 3.
    Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Electronic address:
    Objectives: To validate the prognostic value of the new American Joint Committee on Cancer (AJCC) staging system (eighth edition) among different staging contexts (clinical vs. pathologic).

    Methods: Surveillance, Epidemiology, and End Results (SEER) database (2010-2014) was accessed through SEER*Stat program and both AJCC seventh and eighth edition stages were assigned for each patient. Read More

    Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC).
    Clin Genitourin Cancer 2017 Jul 14. Epub 2017 Jul 14.
    Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA; Department of Medicine/Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
    Background: Previous data suggests that co-targeting mammalian target of rapamycin and angiogenic pathways may potentiate effects of cytotoxic chemotherapy. We studied combining mammalian target of rapamycin and vascular endothelial growth factor inhibition with docetaxel in castrate-resistant prostate cancer (CRPC).

    Methods: Eligible patients had progressive, metastatic, chemotherapy-naive CRPC. Read More

    Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer.
    Clin Genitourin Cancer 2017 Jul 26. Epub 2017 Jul 26.
    Division of Urology, The University of Texas Medical Branch at Galveston, Galveston, TX. Electronic address:
    Background: The purpose of this study was to examine temporal nationwide utilization patterns and predictors for use of positron emission tomography/computed tomography (PET/CT) in comparison with magnetic resonance imaging (MRI) and computed tomography (CT) among patients diagnosed with bladder cancer.

    Materials And Methods: A total of 36,855 patients aged 66 years or older diagnosed with clinical stage TI-IV, N0M0 bladder cancer from 2004 to 2011 were analyzed. We used multivariable logistic regression analyses to discern factors associated with receipt of imaging within 12 months from diagnosis. Read More

    Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
    Clin Genitourin Cancer 2017 Jul 26. Epub 2017 Jul 26.
    Department of Urology, Chiba Cancer Center Hospital, Chiba, Japan.
    Background: An important clinical question of great interest to clinicians is how to best sequence androgen receptor targeted agents (ARTAs) and chemotherapy for metastatic castration-resistant prostate cancer (mCRPC), but the answer is still unclear.

    Materials And Methods: To evaluate and compare the clinical outcomes of ARTA and docetaxel (DTX) as second-line treatment in the post first-line ARTA, we conducted a retrospective analysis of chemotherapy-naive mCRPC patients who had received sequential treatment with ARTA followed by another ARTA (ARTA-ARTA) or ARTA followed by DTX (ARTA-DTX).

    Results: A total of 97 patients were treated with the ARTA-ARTA sequence and 42 with the ARTA-DTX sequence. Read More

    Role of the Coagulation System in Genitourinary Cancers: Review.
    Clin Genitourin Cancer 2017 Jul 26. Epub 2017 Jul 26.
    Department of Urology, Ulm University Medical Centre, Ulm, Germany.
    Tumor progression is associated with aberrant hemostasis, and patients with malignant diseases have an elevated risk of developing thrombosis. A crosstalk among the vascular endothelium, components of the coagulation cascade, and cancer cells transforms the intravascular milieu to a prothrombotic, proinflammatory, and cell-adhesive state. We review the existing evidence on activation of the coagulation system and its implication in genitourinary malignancies and discuss the potential therapeutic benefit of antithrombotic agents. Read More

    Adverse Pathology After Neoadjuvant Chemotherapy and Radical Cystectomy: The Role of Adjuvant Chemotherapy.
    Clin Genitourin Cancer 2017 Jul 22. Epub 2017 Jul 22.
    Department of Urology, Mayo Clinic, Rochester, MN. Electronic address:
    Background: The current guidelines do not recommend adjuvant chemotherapy (AC) for patients with adverse pathologic findings after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) for bladder cancer. We sought to evaluate the association of AC with overall survival (OS) in these patients.

    Materials And Methods: The National Cancer Database was used to identify patients with adverse pathologic findings (ypT3N0, ypT4N0, or ypTanyN1-N3) after NAC and RC for bladder cancer from 2006 to 2012. Read More

    Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy.
    Clin Genitourin Cancer 2017 Jul 26. Epub 2017 Jul 26.
    Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. Electronic address:
    Introduction: We evaluated the influence of perinephric fat invasion (PFI) compared with sinus fat invasion (SFI) on disease-free survival (DFS) and cancer-specific survival (CSS) after partial nephrectomy (PN) for stage pT3a renal cell carcinoma (RCC).

    Materials And Methods: Data were recorded from the consecutive records of patients who had undergone underwent PN for cT1-T2 RCC from 2007 to 2016. Of these patients, 143 had stage pT3a with SFI or PFI found on final pathologic examination. Read More

    Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder.
    Clin Genitourin Cancer 2017 Jul 22. Epub 2017 Jul 22.
    Department of Public Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
    Objective: The efficacy of chemotherapy on UCSD is not known. This study was conducted to investigate the efficacy of cisplatin-based chemotherapy and prognosis of patients with UC with or without SD of the bladder.

    Methods: Patients with invasive bladder cancer (clinical T3-4aN0M0) who were treated between March 2003 and March 2015 with 2 or 3 cycles of neoadjuvant chemotherapy followed by radical cystectomy were retrospectively evaluated. Read More

    Predictors for Intravesical Recurrence Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A National Multicenter Analysis.
    Clin Genitourin Cancer 2017 Jul 22. Epub 2017 Jul 22.
    Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Korea. Electronic address:
    Introduction: The purpose of this study was to identify the prognostic impact of intravesical recurrence (IVR) on oncologic outcomes and the clinicopathologic factors that predict IVR in patients who undergo radical nephroureterectomy (RNU) for upper tract urothelial carcinoma.

    Patients And Methods: Between January 2000 and December 2015, 760 patients with upper tract urothelial carcinoma underwent RNU at 5 institutions in Korea, and patient data were retrospectively collected. Clinicopathologic factors were analyzed for intravesical recurrence-free survival, cancer-specific survival (CSS), and overall survival (OS). Read More

    Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder.
    Clin Genitourin Cancer 2017 Jul 14. Epub 2017 Jul 14.
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:
    Purpose: Evaluate oncologic outcomes of patients with cT1 nested variant (NV) of urothelial carcinoma (UC) and compare with cases of pure UC of the bladder.

    Materials And Methods: We retrospectively identified 30 patients with NV who, between 1997 and 2012, underwent transurethral resection with T1 tumor stage, followed by restaging transurethral resection within 3 months confirming non-muscle-invasive disease. Radical cystectomy within 3 months of restaging transurethral resection was considered "early" treatment. Read More

    Utility of Anterior Zone Biopsy in Men Enrolled in Active Surveillance for Prostate Cancer.
    Clin Genitourin Cancer 2017 Jul 14. Epub 2017 Jul 14.
    Department of Urology, University of California, Davis, Sacramento, CA; University of California Davis Comprehensive Cancer Center, Sacramento, CA; Division of Urology, Department of Surgery, VA Northern California Health Care System, Sacramento, CA. Electronic address:
    Background: Anterior zone (AZ) disease is present in one-fifth of men with newly diagnosed prostate cancer and has been associated with poor pathologic features. However, anterior targeted biopsies are not a routine part of active surveillance (AS) protocols. Our purpose is to assess the utility of AZ sampling for prostate biopsy in patients undergoing surveillance for low-risk prostate cancer. Read More

    Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma.
    Clin Genitourin Cancer 2017 Jul 14. Epub 2017 Jul 14.
    Genitourinary Program, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN. Electronic address:
    Background: Based on the tumor-driven concomitant activation of angiogenesis and coagulation we conducted a phase I combination study of sunitinib with the low molecular weight heparin dalteparin in patients with metastatic clear cell renal cell carcinoma (ccRCC).

    Materials And Methods: Patients received standard treatment with sunitinib (50 mg daily, 4 weeks on, 2 weeks off). During the second week of no sunitinib in the first cycle (week 6) patients received dalteparin monotherapy (in escalating doses). Read More

    Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting.
    Clin Genitourin Cancer 2017 Jun 19. Epub 2017 Jun 19.
    Analysis Group, Inc, Boston, MA.
    Background: In metastatic castration-resistant prostate cancer (mCRPC), optimal treatment sequences are unknown. We assessed second-line taxane (TT) versus androgen receptor-targeted therapy (ART), after initial ART failure, in United States oncology community practices.

    Patients And Methods: Using electronic medical records, patients with mCRPC receiving first-line ART and second-line therapy (TT, ART) were identified. Read More

    Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
    Clin Genitourin Cancer 2017 Jun 29. Epub 2017 Jun 29.
    Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
    Background: Although targeted therapies with inhibitors of the vascular endothelial growth factor (VEGF) are the mainstay of treatment for metastatic renal cell carcinoma, there are limited data on the outcome of patients with long-term response to this treatment.

    Patients And Methods: In a retrospective, registry-based study, patients continuously treated with first-line anti-VEGF agents for at least 24 months were included. In total, 219 patients had evaluable data and were included in the outcome analysis. Read More

    Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials.
    Clin Genitourin Cancer 2017 Jun 20. Epub 2017 Jun 20.
    Gustave Roussy, Villejuif Cedex, France.
    Background: We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) > 18 months.

    Patients And Methods: A retrospective analysis of data from 5714 patients with mRCC treated with sunitinib in 8 phase II/III clinical trials and the expanded access program. Duration on-study and objective response rate (ORR) were compared between LTRs and patients with PFS ≤ 18 months ("others"). Read More

    Prostate Cancer Screening in a New Era of Genetics.
    Clin Genitourin Cancer 2017 May 31. Epub 2017 May 31.
    Department of Medicine, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA.
    Men who inherit pathogenic germline mutations in BRCA2 and BRCA1 are at increased risk of developing aggressive prostate cancer, and those with germline mutations in other DNA repair genes such as ATM, CHEK2, and MSH2/MSH6 may also have increased risks. Although clinically important, there is lack of specific guidance regarding management strategies for men at increased risk owing to germline mutation status or family history of aggressive prostate cancer. We review prostate cancer genetic risk factors and the ongoing IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) screening study. Read More

    Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma.
    Clin Genitourin Cancer 2017 Jun 19. Epub 2017 Jun 19.
    Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY. Electronic address:
    Purpose: The purpose of this study was to evaluate the predictive and prognostic role of preoperative thrombocytosis (TC) in upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU) in a large multi-institutional cohort of patients.

    Methods: Records of 2492 patients undergoing RNU for non-metastatic UTUC between 1990 and 2008 were retrospectively analyzed. Preoperative TC was defined as a platelet count > 400 × 10(9)/L, irrespective of gender type. Read More

    Müllerian Adenosarcoma of the Urinary Bladder: Clinicopathologic and Immunohistochemical Features With Novel Genetic Aberrations.
    Clin Genitourin Cancer 2017 May 25. Epub 2017 May 25.
    Department of Pathology, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. Electronic address:
    Background: Müllerian adenosarcoma is a biphasic neoplasm most commonly occurring in the uterus and less frequently of the ovary. It has been rarely described to occur in other sites such as peritoneum and liver.

    Patients And Methods: In this study, we report the clinicopathologic, immunohistochemical and molecular features of a primary Müllerian adenosarcoma of the urinary bladder in a 62-year-old woman. Read More

    Paraganglioma of the Urinary Bladder: A Series of 22 Cases in a Single Center.
    Clin Genitourin Cancer 2017 Mar 28. Epub 2017 Mar 28.
    Department of Urology, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/Chinese PLA Medical School, Beijing, P.R. China. Electronic address:
    Objective: Paraganglioma of the urinary bladder (PUB) is rare in bladder cancer, and currently, a study examining large number of cases from a single center has not been reported. This study aimed to present the clinical features, treatments, pathological characteristics, and prognosis of PUB.

    Patients And Methods: From January 2006 to June 2016, 22 patients were pathologically diagnosed with PUB in our hospital. Read More

    Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors: A 25-year Single-center Experience.
    Clin Genitourin Cancer 2017 Jun 1. Epub 2017 Jun 1.
    First Department of Oncology, Faculty of Medicine, Comenius University, St Elisabeth Cancer Institute, Bratislava, Slovak Republic. Electronic address:
    Background: Surveillance after orchiectomy alone has become popular in the management of clinical stage I nonseminomatous germ cell testicular tumors (CSI NSGCTT). Efforts to identify patients at high risk of disease progression led to a search for risk factors in CSI NSGCTT. The aim of this study was to analyze a 25-year single-center experience with risk-adapted therapeutic approaches-active surveillance (AS) versus adjuvant chemotherapy (ACT). Read More

    Low Pressure Robot-assisted Radical Prostatectomy With the AirSeal System at OLV Hospital: Results From a Prospective Study.
    Clin Genitourin Cancer 2017 Jun 2. Epub 2017 Jun 2.
    Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium; ORSI Academy, Melle, Belgium. Electronic address:
    Background: Limited studies examined effects of pneumoperiotneum during robot-assisted radical prostatectomy (RARP) and with AirSeal. The aim of this study was to assess the effect on hemodynamics of a lower pressure pneumoperitoneum (8 mmHg) with AirSeal, during RARP in steep Trendelenburg 45° (ST).

    Materials And Methods: This is an institutional review board-approved, prospective, interventional, single-center study including patients treated with RARP at OLV Hospital by one extremely experienced surgeon (July 2015-February 2016). Read More

    A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer.
    Clin Genitourin Cancer 2017 Jun 8. Epub 2017 Jun 8.
    Division of Oncology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA. Electronic address:
    Background: AEZS-108 (zoptarelin doxorubicin) is a cytotoxic hybrid molecule consisting of doxorubicin covalently coupled with a luteinizing hormone-releasing hormone (LHRH) analogue, which selectively targets doxorubicin to tumor cells expressing LHRH receptors. We report the clinical efficacy of AEZS-108 in a phase II trial in men with metastatic castrate-resistant prostate cancer who had disease progression after taxane-based chemotherapy.

    Patients And Methods: Patients received AEZS-108 210 mg/m(2) intravenously every 3 weeks. Read More

    A Walking Intervention Among Men With Prostate Cancer: A Pilot Study.
    Clin Genitourin Cancer 2017 May 31. Epub 2017 May 31.
    Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
    Background: Men diagnosed with prostate cancer have increased risk for disease progression, cardiovascular events, and impairments in quality of life. This pilot study evaluated the feasibility of a randomized walking group intervention to improve quality of life, circulating biomarkers, and morbidity among men with newly diagnosed prostate cancer.

    Methods: Men were recruited at Örebro University Hospital, Sweden, and randomized to an 11-week walking group intervention (n = 21) or usual care (n = 20). Read More

    Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity.
    Clin Genitourin Cancer 2017 Jun 8. Epub 2017 Jun 8.
    South Australian Prostate Cancer Clinical Outcomes Collaborative, Adelaide, Australia; Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, Australia; Flinders Centre for Innovation in Cancer, Adelaide, Australia; Centre for Population Health Research, University of South Australia, Adelaide, Australia; Discipline of Surgery, University of Adelaide, Adelaide, Australia.
    Prostate cancer is a heterogeneous disease whose therapies frequently have adverse effects. Informed patient counseling regarding likely clinical outcomes is therefore important. In this systematic review we aimed to identify all external validations of tools that are used to predict clinical outcomes in patients undergoing radical prostatectomy and evaluate which are optimum for clinical implementation. Read More

    High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
    Clin Genitourin Cancer 2017 Jun 3. Epub 2017 Jun 3.
    Division of Genitourinary Medical Oncology, University of California, San Francisco, CA.
    Background: Abiraterone acetate (AA) inhibits androgen biosynthesis and prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) when combined with prednisone (P). Resistance to therapy remains incompletely understood. In this open-label, single-arm, multicenter phase II study we investigated the clinical benefit of increasing the dose of AA at the time of resistance to standard-dose therapy. Read More

    1 OF 22